WJA
DGX icon

Willis Johnson & Associates’s Quest Diagnostics DGX Stock Holding History

Willis Johnson & Associates’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,208
Closed -$237K – 121
2026
Q1 		$237K Buy
1,208
+8
+0.7% +$1.55K 0.01% 173
2025
Q4 		$208K Buy
1,200
+7
+0.6% +$1.27K 0.01% 173
2025
Q3 		$227K Buy
+1,193
New +$212K 0.01% 165

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Willis Johnson & Associates's DGX Position: Q2 2026 in Review

Willis Johnson & Associates sold out of Quest Diagnostics (DGX) in Q2 2026, closing a stake of 1,208 shares — an estimated $237K sold.

Willis Johnson & Associates first reported a position in DGX in Q3 2025 and held it in 3 quarters. The position peaked at $237K in Q1 2026. 1,111 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Willis Johnson & Associates reported no remaining Quest Diagnostics position as of Q2 2026 after selling out during the quarter.
  • Willis Johnson & Associates sold 1,208 Quest Diagnostics shares in Q2 2026, an estimated $237K.
  • Willis Johnson & Associates first reported a position in Quest Diagnostics in Q3 2025 and held it in 3 quarters.
  • Willis Johnson & Associates's Quest Diagnostics position peaked at $237K in Q1 2026.
  • 1,111 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Willis Johnson & Associates's 13F filing for Q2 2026, filed 13 Aug 2026.